Comparative Evaluation of the Evolution of Arterial and Microcirculatory Endothelial Function in Obese Patients With Type-2 Diabetes Versus Non-diabetic Obese Patients After a First Bariatric Surgery

NCT ID: NCT03636243

Last Updated: 2025-01-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-15

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The weight reduction obtained after a first bariatric surgery would improve the vascular (correction of endothelial dysfunction, improvement of arterial wall compliance and evolution of the atherothrombotic process) and microcirculatory function in obese patients with type-2 diabetes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bariatric Surgery Obese Type2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group of obese patients with type-2 diabetes

Group Type OTHER

Vascularly biological assessment

Intervention Type BIOLOGICAL

22.5 ml of blood will be collected at day -15, month 3 and month 12.

Analysis of vasomotor endothelial function

Intervention Type BIOLOGICAL

Evaluation of the peripheral endothelial function by digital tonometry using the 'EndoPATTM2000' system \[Itamar Medical Ltd., Caeserea, Israel\] before and after induction of post occlusive reactive hyperemia at day -15, month 3 and month 12.

Analysis of arterial compliance

Intervention Type BIOLOGICAL

Evaluation of the aortic pulse wave velocity in the aortofemoral segment or in the periphery (on the arm-ankle segment) by calculation of central aortic pressure (CAP) using the tonometric system 'Complior ™' \[Alam Medical, France\] at day -15, month 3 and month 12

Exploration of microcirculation

Intervention Type BIOLOGICAL

The microcirculation exploration via analysis of the curves recorded by Laser Doppler at day -15, month 3 and month 12

Venous Doppler Ultrasound

Intervention Type BIOLOGICAL

aneurysm screening at day -15, month 3 and month 12

Arterial pressure measurement

Intervention Type BIOLOGICAL

measurement of the systolic pressure at the toe using the SysToe™ device, and measurement of systolic and diastolic blood pressure using the Dinamap™ device at day -15, month 3 and month 12

Intima-Media Thickness measurement

Intervention Type BIOLOGICAL

Intima-Media Thickness measurement using an ultrasound machine at day -15, month 3 and month 12

Exploration of neuropathy

Intervention Type BIOLOGICAL

non-invasive measurement of sudomotor function by SUDOSCAN at day -15, month 3 and month 12

level of physical activity

Intervention Type BEHAVIORAL

pedometer collecting the number of steps during the four days before visits at day -15, month 3 and month 12

Group of non-diabetic obese patients

Group Type OTHER

Vascularly biological assessment

Intervention Type BIOLOGICAL

22.5 ml of blood will be collected at day -15, month 3 and month 12.

Analysis of vasomotor endothelial function

Intervention Type BIOLOGICAL

Evaluation of the peripheral endothelial function by digital tonometry using the 'EndoPATTM2000' system \[Itamar Medical Ltd., Caeserea, Israel\] before and after induction of post occlusive reactive hyperemia at day -15, month 3 and month 12.

Analysis of arterial compliance

Intervention Type BIOLOGICAL

Evaluation of the aortic pulse wave velocity in the aortofemoral segment or in the periphery (on the arm-ankle segment) by calculation of central aortic pressure (CAP) using the tonometric system 'Complior ™' \[Alam Medical, France\] at day -15, month 3 and month 12

Exploration of microcirculation

Intervention Type BIOLOGICAL

The microcirculation exploration via analysis of the curves recorded by Laser Doppler at day -15, month 3 and month 12

Venous Doppler Ultrasound

Intervention Type BIOLOGICAL

aneurysm screening at day -15, month 3 and month 12

Arterial pressure measurement

Intervention Type BIOLOGICAL

measurement of the systolic pressure at the toe using the SysToe™ device, and measurement of systolic and diastolic blood pressure using the Dinamap™ device at day -15, month 3 and month 12

Intima-Media Thickness measurement

Intervention Type BIOLOGICAL

Intima-Media Thickness measurement using an ultrasound machine at day -15, month 3 and month 12

Exploration of neuropathy

Intervention Type BIOLOGICAL

non-invasive measurement of sudomotor function by SUDOSCAN at day -15, month 3 and month 12

level of physical activity

Intervention Type BEHAVIORAL

pedometer collecting the number of steps during the four days before visits at day -15, month 3 and month 12

thoracic scanner

Intervention Type OTHER

non-injected thoracic scanner visit at month 3

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vascularly biological assessment

22.5 ml of blood will be collected at day -15, month 3 and month 12.

Intervention Type BIOLOGICAL

Analysis of vasomotor endothelial function

Evaluation of the peripheral endothelial function by digital tonometry using the 'EndoPATTM2000' system \[Itamar Medical Ltd., Caeserea, Israel\] before and after induction of post occlusive reactive hyperemia at day -15, month 3 and month 12.

Intervention Type BIOLOGICAL

Analysis of arterial compliance

Evaluation of the aortic pulse wave velocity in the aortofemoral segment or in the periphery (on the arm-ankle segment) by calculation of central aortic pressure (CAP) using the tonometric system 'Complior ™' \[Alam Medical, France\] at day -15, month 3 and month 12

Intervention Type BIOLOGICAL

Exploration of microcirculation

The microcirculation exploration via analysis of the curves recorded by Laser Doppler at day -15, month 3 and month 12

Intervention Type BIOLOGICAL

Venous Doppler Ultrasound

aneurysm screening at day -15, month 3 and month 12

Intervention Type BIOLOGICAL

Arterial pressure measurement

measurement of the systolic pressure at the toe using the SysToe™ device, and measurement of systolic and diastolic blood pressure using the Dinamap™ device at day -15, month 3 and month 12

Intervention Type BIOLOGICAL

Intima-Media Thickness measurement

Intima-Media Thickness measurement using an ultrasound machine at day -15, month 3 and month 12

Intervention Type BIOLOGICAL

Exploration of neuropathy

non-invasive measurement of sudomotor function by SUDOSCAN at day -15, month 3 and month 12

Intervention Type BIOLOGICAL

level of physical activity

pedometer collecting the number of steps during the four days before visits at day -15, month 3 and month 12

Intervention Type BEHAVIORAL

thoracic scanner

non-injected thoracic scanner visit at month 3

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient is at least 18 years old and under 70 years old
* The patient is available for a follow-up of 12 months
* The patient signed the consent form
* The patient must be affiliated or beneficiary to an health care plan
* The patient is followed in hospital day care in the endocrine and metabolic disorders department at Nimes University Hospital for a first bariatric surgery

Exclusion Criteria

* The subject participates in another interventional study.
* The subject is in an exclusion period determined by a previous study.
* The subject is under the protection of justice, guardianship or curatorship.
* The subject refuses to sign the consent.
* It is not possible to give the subject informed information.
* The patient is pregnant or breastfeeding.
* Subject with known advanced atherothrombotic disease (arterial disease of the lower limbs, significant carotid plaque (generating stenosis\> 50%), history of myocardial infarction, stroke)
* The subject is type 1 diabetic.
* The subject has already had a bariatric surgery.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Nīmes

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Antonia PEREZ-MARTIN, Pr

Role: PRINCIPAL_INVESTIGATOR

Nîmes University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Nimes

Nîmes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIMAO/2017-02/APM-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nantes Bariatric Surgery Cohort
NCT06625762 NOT_YET_RECRUITING NA